The global animal health industry is at a strategic inflection point. The market reached approximately $70 billion in 2025 and is projected to grow at a mid-to-high single-digit CAGR through 2030, driven by companion animal medicalization, livestock productivity demands, and the rapid expansion of veterinary diagnostics. Long-acting parasiticides are reshaping companion animal care — Boehringer Ingelheim's NEXGARD reached $1.5 billion in 2025 sales, Zoetis's Simparica Trio surpassed $1 billion in U.S. sales, and Merck Animal Health's BRAVECTO QUANTUM gained FDA approval as the first once-yearly injectable parasiticide for dogs. Veterinary diagnostics is growing at low double-digit rates as IDEXX and competitors deploy AI-enabled point-of-care platforms and reference lab automation. The World's 10 Leading Suppliers are simultaneously restructuring portfolios, integrating monoclonal antibody platforms, and deploying AI across R&D and manufacturing — creating significant commercial opportunities for organizations that understand where integration is happening fastest.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

The High-Growth Opportunities and Integration Strategies Assessed in This Report Include:
• Companion Animal Monoclonal Antibodies — Osteoarthritis Pain, Dermatitis, and Oncology Therapeutics
• Long-Acting Parasiticide Platforms — Once-Yearly Injectables and Durable Biologics
• Veterinary Diagnostics and Point-of-Care Testing — AI-Enabled Analyzers, Reference Lab Automation
• Companion Animal Oncology — Lymphoma Screening, Mast Cell Tumor Diagnostics, Targeted Therapeutics
• Feline Chronic Kidney Disease — Estimated $3-4 Billion Addressable Opportunity
• JAK Inhibitors and Dermatology — Second-Generation Therapeutics for Canine Pruritus
• Aquaculture Health — Vaccines, Biosecurity, and Nutritional Solutions for Fish and Shellfish
• Avian Influenza and African Swine Fever Vaccines — Disease Outbreak Response Platforms
• Digital Herd Management and Precision Livestock Farming — Sensor Data, Wearables, and AI Analytics
• Antimicrobial Stewardship Solutions — Narrow-Spectrum Drugs, Autogenous Vaccines, and Probiotic Feed Additives

Companies Analyzed in This Report:
Boehringer Ingelheim Animal Health
Ceva Santé Animale
Dechra Pharmaceuticals
Elanco Animal Health
IDEXX Laboratories
Merck Animal Health
Phibro Animal Health
Vetoquinol
Virbac
Zoetis

The Analysis of Each Company Includes:
• Strategic Directions and Corporate Priorities
• Financial Performance and Revenue Breakdown
• SWOT Analysis
• Technology and Innovation Programs
• M&A, Partnerships and Alliances
• Market Positioning and Competitive Strategy
• Integration Roadmap and 2030 Outlook

Topics Covered
• Companion Animal Therapeutics Integration — Monoclonal Antibodies, JAK Inhibitors, Long-Acting Biologics
• Veterinary Diagnostics Integration — Point-of-Care Analyzers, Reference Labs, AI Imaging
• Parasiticide Portfolio Integration — Yearly Injectables, Topical and Oral Combinations
• Livestock Vaccines and Biologics Integration — HPAI, ASF, Bovine and Poultry Disease Programs
• Companion Animal Oncology Integration — Diagnostics-to-Therapeutics Continuum
• Aquaculture Health Integration — Vaccines, Biosecurity, and Production-Animal Crossover
• Digital and AI Integration — Veterinary Software, Telemedicine, Practice Management
• Antimicrobial Stewardship Integration — Narrow-Spectrum, Probiotic, and Autogenous Solutions